Navigation Links
Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
Date:10/5/2009

BASKING RIDGE, N.J., Oct. 5 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the Japan Biopharma Conference 2009 at the Conrad Hotel in Tokyo, Japan. Dr. Mazzo's presentation is scheduled for 2:40pm (GMT +9:00) on October 6, 2009. The Conference brings together premier biotechnology companies from North America and Europe with influential Japanese licensing and business development executives. Dr. Mazzo's presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1 is intended for application i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
2. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
3. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
4. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
5. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
6. Regado Biosciences Expands Medical Advisory Board
7. Regado Biosciences Establishes Medical Advisory Board
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
11. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., Mass., Nov. 19 Arlington Medical...the leading driver of antibiotic selection in noso...ity against gram-positive and gram-negative pathog...e nosocomial pneumonia, surveyed European physicia... provide appropriate coverage against common patho...
(Date:11/19/2009)...nored by latest award for revolutionary hearing ai...ovember 16, 2009 -- Popular Science Magazine has n... from InSound Medical a winner of its coveted Best...    Chosen from thousands of e...earing canal for up to four months while providing...
(Date:11/18/2009)...tted postage stamp that can sniff out poisonous ga... As reported in the Sept. 13 issue of the journal...at the University of Illinois have developed an ar...ndustrial chemicals (TICs) that is simple, fast an...is sensor array could be useful in detecting high ...
(Date:11/18/2009)... U.K. and CLEVELAND, Nov. 18 TREK ...s and premier provider of diagnostic systems and s...expanded its East Grinstead, U.K., manufacturing a...asing global demand for its Sensititre® produ...ing. The expanded facility has been fully validate...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 4
... March 20 ADVENTRX Pharmaceuticals, Inc. (NYSE Am...3, it will reduce its full-time workforce to five ...f its development activities and fundamental busin...mmate a strategic transaction or otherwise obtain ...will consist of its Chief Business Officer and Sen...
...arch 20 /PRNewswire-FirstCall/ - Oncolytics Biotec...interim clinical results from its Phase I/II U.K. ...oplatin for patients with advanced cancers were pr...icating Oncolytic Virus Therapeutics. The meeting ... 22nd, 2009. The principal investigator for the tr...
...rch 20 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... an agreement with Lifeline Biotechnologies, Inc. ...scope product line to Lifeline Biotechnologies for...her consideration. Solos Endoscopy originally pur...in 2007. , , Lifeline Biotechnologies has agreed ...
Other Biology Technology:ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial 3Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2
(Date:11/20/2009)...rth Grafton, Mass., November 19, 2009 The estimat...dustry may be at risk of developing respiratory sy...ording to a questionnaire study undertaken earlier...Cummings School of Veterinary Medicine. , The st...n workersfound that 50 percent of individuals work...
(Date:11/20/2009)...his release is available in German . , In t...l Investigation , Dr. Stefanie Eyerich and Dr. Kil...perial College London and Istituto Dermopatico del... discovery. It represents a milestone on the way t...y skin diseases such as psoriasis and allergic rea...
(Date:11/20/2009)...AMPAIGN, Ill. In a new study, researchers report ...kers can have a helpful, or harmful, effect on the... The study, which appears in the journal Circulat...t both the alpha- and beta-receptors on the heart ... while those that target only the beta-receptors c...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2Health Plans Return to Airwaves in Support of Bipartisan Reform 52104 1Health Plans Return to Airwaves in Support of Bipartisan Reform 52104 2Echo Therapeutics to Present at Jessup 26 Lamont 2009 Growth Stock Conference 52099 1Echo Therapeutics to Present at Jessup 26 Lamont 2009 Growth Stock Conference 52099 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 1New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 3New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 4New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 6
...t allergies successfully prevented allergic reacti...in a test tube, University of California, Los Ange...f Nature Medicine, available online now. In the fu...ts could lead to a new therapy not only for human ...llergies such as those to peanuts. , The National ...
...rch 30th edition of the prestigious scientific jou...tion of the UK,s national academy of science) show...mon farms to wild salmon populations is much large...his quantitative analysis of parasite transfer is ... is the first to isolate and measure the impact of...
...(mtDNA) play,an important role in the development ...tists at Emory University School of Medicine and t...are published online,this week in the Proceedings ...ondrial DNA, which is separate from nuclear DNA, i... the cytoplasm outside of,each cell,s nucleus. The...
Other Biology News:Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Researchers reveal the infectious impact of salmon farms on wild salmon 2Researchers reveal the infectious impact of salmon farms on wild salmon 3Researchers reveal the infectious impact of salmon farms on wild salmon 4Mitochondrial DNA mutations play significant role in prostate cancer 2
Custom siRNA, HPLC purified, annealed from Ambion
Silencer Validated siRNA 5 nmol from Ambion
Mouse Anti-Cyclophilin D Monoclonal Antibody, Unconjugated, Clone PADZC006 from Invitrogen
Fok I from Promega
Biology Products: